PDE4A and frontotemporal dementia: FDA-approved PDE4 inhibitors alleviate the dominant toxicity of ALS-FTD-associated CHCHD10&lt;sup&gt;S59L&lt;/sup&gt; in &lt;i&gt;Drosophila&lt;/i&gt; and human cells.